$ALT
Altimmune Inc

2023 Q3 Form 10-Q Financial Statement

#000132619023000036 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $362.0K $6.000K $8.000K
YoY Change 18000.0% -25.0% -94.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.510M $4.760M $4.410M
YoY Change 0.4% 7.94% 20.54%
% of Gross Profit
Research & Development $18.39M $13.25M $15.99M
YoY Change -9.25% -17.13% 20.5%
% of Gross Profit
Depreciation & Amortization $53.00K
YoY Change -22.57%
% of Gross Profit
Operating Expenses $22.90M $18.01M $20.40M
YoY Change -7.48% -11.71% -18.39%
Operating Profit -$22.54M -$18.01M -$20.40M
YoY Change -8.94% -11.71% -17.97%
Interest Expense $29.00K $2.000K $65.00K
YoY Change -54.69% -96.92% 195.45%
% of Operating Profit
Other Income/Expense, Net $1.869M $1.946M $288.0K
YoY Change 79.88% 575.69% 678.38%
Pretax Income -$20.67M -$16.06M -$20.11M
YoY Change -12.83% -20.12% -19.01%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$20.67M -$16.06M -$20.11M
YoY Change -12.1% -20.12% -19.01%
Net Earnings / Revenue -5710.22% -267683.33% -251337.5%
Basic Earnings Per Share -$0.39 -$0.32 -$0.42
Diluted Earnings Per Share -$0.39 -$0.32 -$0.42
COMMON SHARES
Basic Shares Outstanding 52.69M 49.29M 47.50M
Diluted Shares Outstanding 53.63M 50.69M 47.50M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $140.8M $160.0M $184.8M
YoY Change -30.24% -13.42% -15.18%
Cash & Equivalents $86.86M $102.4M $135.9M
Short-Term Investments $53.90M $57.60M $48.90M
Other Short-Term Assets $7.600M $5.863M $4.653M
YoY Change 57.55% 26.0% -50.75%
Inventory
Prepaid Expenses
Receivables $900.0K $136.0K $195.0K
Other Receivables $3.600M $3.579M $5.900M
Total Short-Term Assets $153.0M $169.5M $195.5M
YoY Change -27.51% -13.28% -18.07%
LONG-TERM ASSETS
Property, Plant & Equipment $765.0K $882.0K $1.236M
YoY Change -34.73% -28.64% -73.98%
Goodwill
YoY Change
Intangibles $12.42M
YoY Change -4.15%
Long-Term Investments
YoY Change
Other Assets $425.0K $483.0K $747.0K
YoY Change -37.68% -35.34% -19.58%
Total Long-Term Assets $13.61M $13.78M $14.40M
YoY Change -4.65% -4.29% -22.72%
TOTAL ASSETS
Total Short-Term Assets $153.0M $169.5M $195.5M
Total Long-Term Assets $13.61M $13.78M $14.40M
Total Assets $166.6M $183.3M $209.9M
YoY Change -26.06% -12.67% -18.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.046M $4.035M $2.872M
YoY Change 114.66% 40.49% 102.08%
Accrued Expenses $8.800M $7.346M $10.97M
YoY Change -33.1% -33.05% 42.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.87M $11.44M $13.85M
YoY Change -24.59% -17.39% 52.21%
LONG-TERM LIABILITIES
Long-Term Debt $4.305M $4.165M $1.526M
YoY Change -4.46% 172.94% -5.64%
Other Long-Term Liabilities $46.00K $52.00K $372.0K
YoY Change -30.3% -86.02% 311.35%
Total Long-Term Liabilities $4.351M $4.217M $1.898M
YoY Change -4.83% 122.18% 11.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.87M $11.44M $13.85M
Total Long-Term Liabilities $4.351M $4.217M $1.898M
Total Liabilities $16.18M $15.60M $15.37M
YoY Change -20.11% 1.5% -3.83%
SHAREHOLDERS EQUITY
Retained Earnings -$434.7M -$414.0M -$332.7M
YoY Change 22.03% 24.44% 41.11%
Common Stock $5.000K $5.000K $5.000K
YoY Change 0.0% 0.0% 26.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $150.4M $167.7M $194.5M
YoY Change
Total Liabilities & Shareholders Equity $166.6M $183.3M $209.9M
YoY Change -26.06% -12.67% -18.41%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$20.67M -$16.06M -$20.11M
YoY Change -12.1% -20.12% -19.01%
Depreciation, Depletion And Amortization $53.00K
YoY Change -22.57%
Cash From Operating Activities -$20.49M -$19.38M -$16.70M
YoY Change 36.15% 16.04% -11.74%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$4.000K -$19.00K
YoY Change -100.0% -78.95% -99.76%
Acquisitions
YoY Change
Other Investing Activities $4.400M $3.983M -$48.95M
YoY Change -117.36% -108.14% -249.02%
Cash From Investing Activities $4.400M $3.987M -$48.97M
YoY Change -117.32% -108.14% -295.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 590.0K 13.07M 21.58M
YoY Change -98.16% -39.47% 19.79%
NET CHANGE
Cash From Operating Activities -20.49M -19.38M -16.70M
Cash From Investing Activities 4.400M 3.987M -48.97M
Cash From Financing Activities 590.0K 13.07M 21.58M
Net Change In Cash -15.50M -2.331M -44.09M
YoY Change 84.68% -94.71% -282.45%
FREE CASH FLOW
Cash From Operating Activities -$20.49M -$19.38M -$16.70M
Capital Expenditures $0.00 -$4.000K -$19.00K
Free Cash Flow -$20.49M -$19.38M -$16.69M
YoY Change 36.69% 16.15% 49.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50691558
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47502599
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50410184
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44150835
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52657661
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49199845
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001326190
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52657661
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32587
dei Entity Registrant Name
EntityRegistrantName
ALTIMMUNE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-2726770
dei Entity Address Address Line1
EntityAddressAddressLine1
910 Clopper Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 201S
dei Entity Address City Or Town
EntityAddressCityOrTown
Gaithersburg
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20878
dei City Area Code
CityAreaCode
240
dei Local Phone Number
LocalPhoneNumber
654-1450
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ALT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52686426
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102352000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111097000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
41000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
34000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102393000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111131000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
57602000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
73783000
CY2023Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
136000
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
173000
CY2023Q2 alt Income Taxes And Research Development Incentive Receivable Current
IncomeTaxesAndResearchDevelopmentIncentiveReceivableCurrent
3579000
CY2022Q4 alt Income Taxes And Research Development Incentive Receivable Current
IncomeTaxesAndResearchDevelopmentIncentiveReceivableCurrent
2368000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5822000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5358000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
169532000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
192813000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
882000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1081000
CY2023Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
12419000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
12419000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
483000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
615000
CY2023Q2 us-gaap Assets
Assets
183316000
CY2022Q4 us-gaap Assets
Assets
206928000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4035000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4804000
CY2023Q2 alt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7402000
CY2022Q4 alt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12250000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11437000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17054000
CY2023Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
4165000
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
4581000
CY2023Q2 us-gaap Liabilities
Liabilities
15602000
CY2022Q4 us-gaap Liabilities
Liabilities
21635000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52657661
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49199845
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
5000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
586908000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
568399000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-414019000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-377884000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5180000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5227000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
167714000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
185293000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
183316000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
206928000
CY2023Q2 us-gaap Revenues
Revenues
6000
CY2022Q2 us-gaap Revenues
Revenues
8000
us-gaap Revenues
Revenues
27000
us-gaap Revenues
Revenues
40000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13253000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15993000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30502000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31097000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4760000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4410000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9291000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8837000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
18013000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
20403000
us-gaap Operating Expenses
OperatingExpenses
39793000
us-gaap Operating Expenses
OperatingExpenses
39934000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18007000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20395000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39766000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39894000
CY2023Q2 us-gaap Interest Expense
InterestExpense
2000
CY2022Q2 us-gaap Interest Expense
InterestExpense
65000
us-gaap Interest Expense
InterestExpense
4000
us-gaap Interest Expense
InterestExpense
127000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1835000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
328000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3503000
us-gaap Investment Income Interest
InvestmentIncomeInterest
349000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
113000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
132000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
135000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1946000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
288000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3631000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
357000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-16061000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-20107000
us-gaap Net Income Loss
NetIncomeLoss
-36135000
us-gaap Net Income Loss
NetIncomeLoss
-39537000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-79000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-120000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
47000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-120000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-16140000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-20227000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-36088000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-39657000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50691558
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47502599
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50410184
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44150835
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
185293000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2675000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
61000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-484000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
135000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
126000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-20074000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
167732000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2786000
CY2023Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-16000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13352000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-79000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-16061000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
167714000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
199135000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2033000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
197000
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-170000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
113000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2990000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-19430000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
184868000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2048000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
403000
CY2022Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-80000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21347000
CY2022Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
6176000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-120000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-20107000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
194535000
us-gaap Profit Loss
ProfitLoss
-36135000
us-gaap Profit Loss
ProfitLoss
-39537000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
86000
us-gaap Share Based Compensation
ShareBasedCompensation
5461000
us-gaap Share Based Compensation
ShareBasedCompensation
4081000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
-861000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
172000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
132000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
134000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-37000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-233000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
250000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3397000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-769000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
838000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4930000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1124000
alt Increase Decrease In Income Taxes And Tax Incentive Receivable
IncreaseDecreaseInIncomeTaxesAndTaxIncentiveReceivable
1211000
alt Increase Decrease In Income Taxes And Tax Incentive Receivable
IncreaseDecreaseInIncomeTaxesAndTaxIncentiveReceivable
490000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38790000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30230000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
60565000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
43229000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
48949000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17289000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48977000
alt Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
195000
alt Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
36000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13352000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24337000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
135000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
113000
alt Payments Of Conditional Economic Incentive
PaymentsOfConditionalEconomicIncentive
90000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
61000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
600000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
500000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
250000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12763000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24764000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8738000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-54443000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111131000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190335000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102393000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135892000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
6176000
CY2023Q2 alt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7402000
CY2022Q4 alt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12250000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">limited to, the valuation of share-based awards, income taxes, and accruals for research and development activities. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</p>
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
73783000
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
57742000
CY2023Q2 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
-140000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
57602000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
73970000
CY2022Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
-187000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
73783000
CY2023Q2 alt Assets Or Liabilities Measured At Fair Value On Non Recurring Basis
AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis
0
CY2022Q4 alt Assets Or Liabilities Measured At Fair Value On Non Recurring Basis
AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis
0
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
903000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1124000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
484000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
596000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.072
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.072
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
263000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
276000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1748000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2955000
CY2023Q2 alt Accrued Research And Development
AccruedResearchAndDevelopment
4800000
CY2022Q4 alt Accrued Research And Development
AccruedResearchAndDevelopment
7295000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
474000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
452000
CY2023Q2 alt Excess Tax Refund Payable
ExcessTaxRefundPayable
56000
CY2022Q4 alt Excess Tax Refund Payable
ExcessTaxRefundPayable
1169000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
61000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
103000
CY2023Q2 alt Research And Development Incentive Credit
ResearchAndDevelopmentIncentiveCredit
3524000
CY2022Q4 alt Research And Development Incentive Credit
ResearchAndDevelopmentIncentiveCredit
3599000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
429000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
672000
CY2023Q2 alt Economic Conditional Incentive Grants
EconomicConditionalIncentiveGrants
160000
CY2022Q4 alt Economic Conditional Incentive Grants
EconomicConditionalIncentiveGrants
250000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
52000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
60000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4165000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4581000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52657661
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1015166
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.66
alt Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P0Y4M24D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4825831
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
726000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2049291
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.68
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
640000
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2776540
alt Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageExercisePrice
10.39
alt Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm
P6Y1M6D
CY2023Q2 alt Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingIntrinsicValue
86000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2786000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2048000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5461000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4081000

Files In Submission

Name View Source Status
0001326190-23-000036-index-headers.html Edgar Link pending
0001326190-23-000036-index.html Edgar Link pending
0001326190-23-000036.txt Edgar Link pending
0001326190-23-000036-xbrl.zip Edgar Link pending
alt-20230630.xsd Edgar Link pending
alt-20230630x10q.htm Edgar Link pending
alt-20230630x10q002.jpg Edgar Link pending
alt-20230630xex31d1.htm Edgar Link pending
alt-20230630xex31d2.htm Edgar Link pending
alt-20230630xex32d1.htm Edgar Link pending
alt-20230630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
alt-20230630_cal.xml Edgar Link unprocessable
alt-20230630_def.xml Edgar Link unprocessable
alt-20230630_lab.xml Edgar Link unprocessable
alt-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
alt-20230630x10q_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending